Recent research papers

2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2000 | 1999 | 1998 | 1997

  1. Foldvari, M. (2020) Preface: Nano-Enabled Medical Applications. Nanomedicine’s Most Cited. Vol. 2., L. Balogh (Editor) Jenny Stanford Publishing (in press)
  2. Chen D.W. and Foldvari, M. (2017). A versatile in vitro bioassay for the screening of neurotrophic factor gene therapy systems to combat blindness. Atlas of Science.
  3. Chen DW, Pauloff K and Foldvari M. (2018). Three-dimensional co-culture bioassay for screening of retinal gene delivery systems. Methods in Molecular Biology (MiMB) series; In: “Retinal Gene Therapy: Methods and Protocols” ed. Wijnholds J. (Springer) 1715:79-88.
  4. Calderon-Nieva D, Bandara-Goonewardene K, Gomis S, Foldvari M. (2017) Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals. Drug Deliv Transl Res DOI 10.1007/s13346-017-0400-9
  5. Foldvari M, Bagonluri M. (2017) Carbon nanotubes as functional excipients for nanomedicines: I. Pharmaceutical properties. Chapter 19, In: Nanomedicine in cancer. L.P. Balogh (ed.) Pan Stanford Publishing, pp 487-522.
  6. Foldvari M, Bagonluri M. (2017) Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Chapter 20, In: Nanomedicine in cancer. L.P. Balogh (ed.) Pan Stanford Publishing, pp 523-548.
  7. Foldvari M. and Kumar P. (2017) Perspectives on dermal delivery of macromolecular drugs. In: Percutaneous penetration enhancers. Drug penetration into/through the skin. Dragicevic-Curic, N. and Maibach, H. (eds.), Springer-Verlag Berlin Heidelberg DOI10.1007/978-3-662-53270-6_21
  8. Foldvari M and Chen, DW. (2016) The intricacies of neurotrophic factor therapy for retinal ganglion cell rescue in glaucoma: a case for gene therapy. Invited Review, Neural Regen. Res.11:875-877.

  9. Foldvari M, Chen DW, Nafissi N, Calderon D, Narsineni L, Rafiee, A. (2016) Non-viral gene therapy: gains and challenges of non-invasive administration methods. Invited review for the North American SpecialIssue; J. Control. Rel. 240:165-190.

  10. Bottini M and Foldvari M (2016) Targeted nanosystems as therapeutic and diagnostic tools: The beautiful voyage of nanomedicine. Nanomedicine: NMB, DOI:

  11. Gharagozlo, M., Majewski S. and Foldvari M. (2015) Therapeutic applications of nanomedicine in autoimmune diseases: From immunosuppression to tolerance induction. Nanomedicine: NBM 11:1003-18.
  12. Nafissi N. and Foldvari M. (2016) Neuroprotective therapies in glaucoma: I. Neurotrophic factor delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 8:240-254. DOI:10.1002/wnan.1361
  13. Nafissi N. and Foldvari M. (2015) Neuroprotective therapies in glaucoma: II. Genetic nanotechnology tools. Front. Neurosci. 9:355.
  14. Foldvari M. and Kumar P. (2016) Permeation enhancement by molecular organization switching (MOS): Biphasic vesicles for the cutaneous delivery of proteins. In: Percutaneous penetration enhancers. Chemical Methods in Penetration Enhancement. Dragicevic-Curic, N. and Maibach, H. (eds.), Springer pp. 309-318.
  15. Elsabahy M, Loureiro MJ, Foldvari M. (2015) Application of nanotechnology in non-invasive topical gene therapy. In: Clinical Nanomedicine. Ed.: R. Bawa, G. Audette, Pan Stanford Press
  16. Foldvari M. and Rafiee A. (2015) Perspectives on using nanoscale delivery systems in dermatological treatment. Curr. Derm. Rep. 4:1-7.
  17. Foldvari M. (2014) Non-invasive ocular drug delivery: Potential transcorneal and other alternative delivery routes for therapeutic molecules in glaucoma. J. Glaucoma 23:8, Suppl 1, S80-82.
  18. Foldvari M (2014) Nanopharmaceutics Innovations in Gene Therapy: Moving Towards Non-Viral and Non-Invasive Delivery Methods. J Nanomedicine Biotherapeutic Discov 4: e135. doi:10.4172/2155-983X.1000e135
  19. Gendelman HE, Balogh LP, Bawa R., Bradbury M, Chang EH, Chiu W, Farokhzad O, Foldvari M, Lanza G, Wang K. (2014) The 4th Annual Meeting of the American Society for Nanomedicine. J. Neuroimmune Pharmacol. 9 (Suppl1) S1-3.
  20. Foldvari M., Gharagozloo M. and Li C. (2014) Nanoparticles for dermal and transdermal delivery: Permeation pathways and applications. In: Torchilin, V. (ed.) Frontiers in nanobiomedical research. World Scientific Publishing, Volume 2, Chapter 7, pp 231-260. doi: 10.1142/9789814520652_0024
  21. Narsineni, and Foldvari M. (2020) Dicationic amino substituted gemini surfactants and their nanoplexes: Improved synthesis and characterization of transfection efficiency and corneal penetration in vitro. Pharm Res 37:144.
  22. GunawardanaT, Ahmed KA, Goonewardene K, Popowich S, Kurukulasuriya S, Karunarathana R, Ayalew, LE, Gupta A, Chow-Lockerbie B, Foldvari M, Tikoo S, Willson P and Gomis S. (2020) CpG-ODN Induces a Dose-Dependent Enrichment of Immunological Niches in the Spleen and Lungs of Neonatal Chicks That Correlates with the Protective Immunity against Escherichia coli. J Immunol Res 2020, Article ID 2704728, 15 pages https://doi.org/10.1155/2020/2704728
  23. Taheri-Araghi S., Chen D.W., Kohandel M., Sivaloganathan S., and Foldvari M. (2019) Tuning effects of cationic to anionic charge ratio and helper lipids on non-viral gene delivery system: a theoretical and experimental study on gemini nanoparticles. Nanoscale 11:1037-1046.
  24. GunawardanaT, Ahmed KA, Goonewardene K, Popowich S, Kurukulasuriya S, Karunarathana R, Gupta A, Chow-Lockerbie B, Foldvari M, Tikoo S, Willson P and Gomis S. (2019) Synthetic CpG-ODN rapidly enriches immune compartments in neonatal chicks to induce protective immunity against bacterial infection. Sci. Reports, 9:1-14.
  25. Chen DW, Narsineni L and Foldvari M. (2018) Multipotent stem cell-derived retinal ganglion cells in 3D culture as tools for neurotrophic factor gene delivery system development. Nanomedicine: NBM, 21:102045.
  26. Miki C, Dewitt-Orr S., Foldvari, M., Moore, M. (2018) Anti-aging properties of phytoglycogen. HPC Today, 13(2):16-18.
  27. Chen DW and Foldvari M. (2018) Retinal multipotent stem cell derived “MiEye” spheroid 3D culture model for preclinical screening of non-viral gene delivery systems. Precision Nanomedicine 1(2):106-123 DOI:10.29016/180711.1
  28. Chen DW, Pauloff K. and Foldvari M. (2018)Three-dimensional co-culture bioassay for screening of retinal gene delivery systems.Methods Mol. Biol. 1715:79-88. doi: 10.1007/978-1-4939-7522-8_6.
  29. Goonewardene K, Popowich S, Gunawardana, T, Gupta A, Kurukulasuriya S, Karunarathna R, Chow-Lockerbie B, Ahmed KA, Tikoo S, Foldvari M, Willson P and Gomis S.. (2017) Intrapulmonary delivery of CpG-ODN microdroplets provides protection against Escherichia coli septicemia in neonatal broiler chickens. Avian Diseases61 (4), 503-511.
  30. Chen DW and Foldvari M. (2016) In vitro bioassay model for screening non-viral neurotrophic factor gene delivery systems for glaucoma treatment. Drug Deliv. Transl. Res. 6:676-685. doi:10.1007/s13346-016-0324-9
  31. ,,,. (2015) A flow cytometric approach to study the mechanism of gene delivery to cells by gemini-lipid nanoparticles: an implication for cell membrane nanoporation. J. Nanobiotechnol. 13:62.
  32. Cunha VR, Guilherme VA, de Paula E, de Araujo DR, Silva RO, Medeiros J VR, Leite JR, Petersen PA, Foldvari M, Petrilli HM, Constantino VR. (2016) Delivery system for mefenamic acid based on the nanocarrier Layered Double Hydroxide: physicochemical characterization and evaluation of anti-inflammatory and antinociceptive potential. 58:629-38.
  33. Huzil JT, Saliaj E, Ivanova M, Gharagozloo M, Loureiro JM, Lamprecht C, Korinek A, Chen DW, Foldvari M. (2015) Selective nuclear localization of siRNA by metallic versus semiconducting single wall carbon nanotubes in keratinocytes. Future Sci. OA FSO17
  34. Dong C, Badea I, Poorghorban M, Verrall R, Foldvari M. (2015) Impact of phospholipids on plasmid packaging and toxicity of gemini nanoparticles. J. Materials Chem. B, 3: 8806-8822.
  35. Foldvari M. (2015) Membrane fusion intermediates captured in liposomal dispersion by freeze-fracturing. F1000 Research 2015,4:4 (doi: )
  36. Gunawardana T, Foldvari, M, Zachar T, Popowich S, Chow-Lockerbie B, Ivanova M, Tikoo S, Kurukulasuriya S, Willson P and Gomis S.. (2015) Protection of neonatal broiler chickens following in ovo injection of oligodeoxynucleotides containing CpG motifs (CpG-ODN) formulated with carbon nanotubes or liposomes. Avian Dis. 59:31-37.
  37. Alqawlaq S, Sivak J, Huzil JT, Ivanova MV, Flanagan, J, Beazely, M, Foldvari M. (2014) Preclinical development and ocular biodistribution of gemini-DNA nanoparticles after intravitreal and topical administration for glaucoma gene therapy. Nanomedicine: NBM 10:1637-1647.
  38. Nafissi N, Alqawlaq S, Foldvari M, Lee E, Spagnuolo P, Slavcev R. (2014) Ministring DNA: Superior gene delivery vector. Mol. Ther. Nucleic Acids 3, e165 doi:10.1038/mtna.2014.16

2013:

Moghadam SH, Saliaj E, Wettig SD, Dong C, Ivanova MV, Huzil JT, Foldvari M. (2013) Mol Pharm 10(6):2248-60.

King M, Kumar P, Michel D, Batta R, Foldvari M. (2013) Eur J Pharm Biopharm 84(3):532-9.

Elsabahy M, Foldvari M. (2013) Curr Pharm Des 19(41):7301-15.

2012:

Alqawlaq, S, Huzil, JT, Ivanova, MV and Foldvari, M. (2012) Nanomedicine (Future Medicine) 7(7):1067-1083.

Foldvari, M and Kumar, P. (2012) . Therapeutic Delivery 3(8):1005-1017.

Donkuru M, Wettig SD, Verrall R, Badea I, Foldvari M. (2012) . J Mater Chem 22:6232-6244.

Badea I,Virtanen C, Verrall R, Rosenberg A,Foldvari M. (2012) . Gene Ther 19: 978-987.

Ivanova M, Lamprecht C, Loureiro MJ, Huzil T, Foldvari M. (2012) . International Journal of Nanomedicine 7:403-415.

2011:

Huzil T, Sivaloganathan S, Kohandel M , Foldvari M. (2011) . Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 3:449–462.

Lamprecht C, Huzil T, Ivanova M, Foldvari M. (2011) . Drug Delivery Letters 1:45-57.

Badea I, Shaterian, N. , Foldvari M. (2011) . Drug Delivery Letters 1:62-66.

Foldvari M, Elsabahy M. (2011) Editorial Hot Topic: . Current Drug Delivery 8:225-226.

Elsabahy M, Nazarali A, Foldvari M. (2011) . Current Drug Delivery 8:235-244.

Singh J, Yang P, Michel D, Verrall RE, Foldvari M, Badea I. (2011) . Current Drug Delivery 8:299-306.

Foldvari M, Badea I, Kumar P, Wettig S, Batta R, King MJ, He Z, Yeboah Z, Gaspar K, Hull P, Shear NH. (2011) . Current Drug Delivery 8:307-319.

2010:

Donkuru M, Badea I, Wettig SD, Verrall RE, Elsabahy M, Foldvari M. (2010) Nanomedicine (Future Medicine) 5:1103-1127.

Yang P, Singh J, Wettig SD, Foldvari M, Verrall RE, Badea I. (2010) . Eur J Pharm Biopharm 75:311-320.

Foldvari M. (2010) . Key Eng Mat 441:53-74.

Foldvari M, Badea I, Wettig SD, Baboolal D, Kumar P, Creagh AL, Haynes CA. (2010) . Mol Pharmaceutics 7:751-762.

2009:

Badea I, Babiuk S, Babiuk L, Foldvari M. (2009) Int J Biomed Nanosci Nanotech1:290-307.

Badea I, Taylor M, Rosenberg A, Foldvari M. (2009) . Rheomatology 48:213-221.

Taghavi A, Allan B, Mutviri G, Foldvari M, Van Kessel A, Willson P, Babiuk L, Potter A, Gomis S. (2009) . Curr Drug Del 6:76-82.

Kumar P, Batta R, LaBine G, Shen J, Gaspar K, Docherty J, Foldvari M. (2009) . Pharm Technol 33:80-86.

2008:

Foldvari M, Bagonluri M. (2008) . Nanomedicine 4:173-182.

Foldvari M, Bagonluri M. (2008) . Nanomedicine 4:183-200.

2007:

Wettig SD, Badea I, Donkuru, M, Verrall RE, Foldvari M. (2007) . J Gene Med 9(8):649-658.

Wang C, Li X, Wettig SD, Badea I, Foldvari M, Verrall RE. (2007) . Phys Chem Chem Phys 9:1616-1628.

Wettig SD, Wang C, Verrall RE, Foldvari M. (2007) . Phys Chem Chem Phys 9:871-877 (appears on front cover).

Wang C, Wettig SD, Foldvari M, Verrall RE. (2007) . Langmuir 23:8995-9001.

Badea I, Wettig SD, Verrall RE, Foldvari M. (2007) . Eur J Pharm Biopharm 65(3):414-422.

2006:

Foldvari M, Wettig SD, Badea I, Verrall RE, Bagonluri M. (2006) . Nanotech 2:400-403.

Alcón VL, Baca-Estrada ME, Potter A, Babiuk LA, Kumar P, Foldvari M. (2006) . Curr Drug Del 3:129-135.

Foldvari M. (2006) . (Editorial) Curr Drug Deliv 3(1):1.

Foldvari M, Babiuk S, and Badea I. (2006) . Curr Drug Deliv 3:17-28.

Wei C, Lyubchenko YL, Ghandehari H, Hanes J, Stebe KJ, Mao HQ, Haynie DT, Tomalia DA, Foldvari M, Monteiro-Riviere N, Simeonova P, Nie S, Mori H, Gilbert S, Needham D. (2006) . Nanomedicine 2:253-263.

Cui Z, Dierling A, Foldvari M. (2006) . Curr Drug Deliv 3:29-35.

Alcón VL, Baca-Estrada ME, Potter A, Babiuk LA, Kumar P, Foldvari M. (2006). . Curr Drug Del 3:129-135.

Alcón VL, Baca-Estrada ME, Potter A, Babiuk LA, Kumar P, Foldvari M. (2006). . Curr Drug Del 3:129-135.

Foldvari M, Kumar P, King M, Batta R, Michel D, Badea I, Wloch M. (2006) . Curr Drug Deliv 3:89-96.

Foldvari M, Badea I, Wettig SD, Verrall RE, Bagonluri M. (2006) . J Exp Nanosci 1:165-176.

2005:

Foldvari M, Badea I, Wettig S, Verrall R and Bagonluri M. (2005) . Nanotech 1:128-131.

Alcón V, Baca-Estrada M, Vega-López M, Willson P, Babiuk LA, Kumar P, Hecker R and Foldvari M. (2005). . AAPS Journal 7(3) Article 57:E566-571.

Alcón VL, Baca-Estrada M, Vega-López MA, Willson P, Babiuk LA, Kumar P and Foldvari M. (2005). Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model. J Pharm Pharmacol 57:955-962.

Alcón VL, Baca-Estrada M, Vega-López MA, Willson P, Babiuk LA, Kumar P and Foldvari M. (2005). Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model. J Pharm Pharmacol 57:955-962.

Badea I, Verrall R, Baca-Estrada M, Tikoo S, Rosenberg A, Kumar P and Foldvari M. (2005) . J Gene Med 7:1200-1214.

Li X, Wettig SD, Wang C, Foldvari M and Verrall RE. (2005) . Phys Chem Chem Phys 7:3172-3178.

2004:

Babiuk S, Baca-Estrada ME, Middleton DM, Hecker R, Babiuk LA, Foldvari M. (2004). . Curr Drug Deliv 1:9-15.

Babiuk S, Baca-Estrada ME, Middleton DM, Hecker R, Babiuk LA, Foldvari M. (2004). . Curr Drug Deliv 1:9-15.

2003:

Babiuk S, Baca-Estrada ME, Foldvari M, Baizer L, Stout R, Storms M, Rabussay D, Widera G, Babiuk L. (2003). . Mol Ther 8:992-998.

Alcón VL, Foldvari M, Snider M, Willson P, Gomis S, Hecker R, Babiuk LA, Baca-Estrada ME. (2003). . Vaccine 21:1811-1814.

Babiuk S, Baca-Estrada ME, Foldvari M, Baizer L, Stout R, Storms M, Rabussay D, Widera G, Babiuk L. (2003). . Mol Ther 8:992-998.

King MJ, Michel D, Foldvari M. (2003) Evidence for lymphatic transport of insulin by topically applied biphasic vesicles. J Pharm Pharmacol 55:1339-1344.

2002:

Jaafari MR, Foldvari M. (2002). . Drug Deliv 9:1-9.

Jaafari MR, Foldvari M. (2002). Targeting of liposomes to melanoma cells with high levels of ICAM-1 expression through adhesive peptides from immunoglobulin domains. J Pharm Sci 91:396-404.

Baca-Estrada ME, Ewen C, Mahony D, Babiuk LA, Wilkie D, Foldvari M. (2002). . Immunology 107:69-76.

Baca-Estrada ME, Ewen C, Mahony D, Babiuk LA, Wilkie D, Foldvari M. (2002). . Immunology 107:69-76.

Babiuk S, Baca-Estrada ME, Pontarollo R, Foldvari M. (2002) Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix). J Pharm Pharmacol 54:1609-1614.

Babiuk S, Baca-Estrada ME, Foldvari M, Storms M, Rabussay D, Widera G, Babiuk LA. (2002) . Vaccine 20:3399-3408.

King MJ, Badea I, Solomon J, Kumar P, Gaspar KJ, Foldvari M. (2002). . Diabetes Technol Ther 4:479-88.

2000:

Foldvari M. (2000). . Pharm Sci Tech Today 3:417-425.

Baca-Estrada ME, Foldvari M, Babiuk SL, Babiuk LA. (2000). . J Biotechnol 83:91-104.

Babiuk S, Baca-Estrada M, Babiuk LA, Ewen C, Foldvari M. (2000). Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control Release 66:199-214.

Baca-Estrada ME, Foldvari M, Snider M, Harding K, Kournikakis B, Babiuk LA, Griebel P. (2000). . Vaccine 18:2203-2211.

Papp Z, Middleton DM, Rontved CM, Foldvari M, Gordon JR, Baca-Estrada ME. (2000). . J Interferon Cytokine Res 20:191-196.

Baca-Estrada ME, Foldvari M, Ewen C, Badea I, Babiuk LA. (2000). . Vaccine 18:1847-1854.

Baca-Estrada ME, Foldvari M, Babiuk SL, Babiuk LA. (2000). . J Biotechnol 83:91-104.

Babiuk S, Baca-Estrada M, Babiuk LA, Ewen C, Foldvari M. (2000). Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control Release 66:199-214.

Baca-Estrada ME, Foldvari M, Snider M, Harding K, Kournikakis B, Babiuk LA, Griebel P. (2000). . Vaccine 18:2203-2211.

Papp Z, Middleton DM, Rontved CM, Foldvari M, Gordon JR, Baca-Estrada ME. (2000). . J Interferon Cytokine Res 20:191-196.

Baca-Estrada ME, Foldvari M, Ewen C, Badea I, Babiuk LA. (2000). . Vaccine 18:1847-1854.

1999:

Jaafari MR, Foldvari M. (1999). . J Drug Target 7:101-112.

Foldvari M. (1999) Novel delivery systems for biotechnology drugs: Recent progress toward improved therapies. Can J Clin Pharmacol 6:65-66.

Baca-Estrada ME, Foldvari M, Snider M. (1999). . J Interferon Cytokine Res 19:455-462.

Baca-Estrada ME, Foldvari M, Snider M. (1999). . J Interferon Cytokine Res 19:455-462.

Babiuk LA, Lewis J, Suradhat S, Baca-Estrada M, Foldvari M, Babiuk S. (1999) . J Biotechnol 73: 131-140.

Foldvari M, Baca-Estrada ME, He Z, Hu J, Attah-Poku S, King M. (1999). . Biotechnol Appl Biochem 30 (Pt 2):129-37.

1998:

Foldvari M, Jaafari MR, Mezei M, Mezei C. (1998) Targeting liposomes through immunoglobulin superfamily domains: Po protein as model. Drug Deliv 5:183-195.

Foldvari M. (1998) Liposomal delivery systems in modern medicine. Drugs (Gyogyszereink) 48:162-171.

Foldvari M, Attah-Poku S, Hu J, Li Q, Hughes H, Babiuk LA, Kruger S. (1998). Palmitoyl derivatives of interferon alpha: potential for cutaneous delivery (PDF). J Pharm Sci 87:1203-1208.

1997:

Baca-Estrada ME, Foldvari M, Snider M, van Drunen Littel-van den Hurk S, Babiuk LA. (1997). . Vaccine 15:1753-1760.

Baca-Estrada ME, Foldvari M, Snider M, van Drunen Littel-van den Hurk S, Babiuk LA. (1997). . Vaccine 15:1753-1760.